Specific Functional Effects of Memantine Treatment in Patients with Moderate to Severe Alzheimer’s DiseaseDoody R.a · Wirth Y.c · Schmitt F.b · Möbius H.J.c
Departments of aNeurology, Baylor College of Medicine, Houston, Tex., and bNeurology and Psychiatry, University of Kentucky, Lexington, Ky., USA; cMerz Pharmaceuticals GmbH, Frankfurt, Germany Dement Geriatr Cogn Disord 2004;18:227–232 (DOI:10.1159/000079833)
Treatment of Alzheimer’s disease (AD) that combats progressive functional deterioration can improve the patient’s quality of life and reduce caregiver burden. Memantine, a moderate affinity N-methyl-D-aspartate receptor antagonist, reduces global deterioration in AD patients and provides cognitive and functional benefits relative to placebo. Two previous studies reported statistically significant benefits of memantine for overall functional ability on the Alzheimer Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADL19), Functional Assessment Staging, and G2 scale. The present study reports a single-item analysis of the ADL scales from the two trials and shows that patients treated with memantine demonstrated a numerical advantage over placebo on all items assessed. These results help to translate the positive effects of memantine into specific aspects of functional ability, information that is relevant to AD patients and their families as well as to researchers interested in the assessment of functional ability in AD clinical trials.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50